Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
David S. Hong, Steven G. DuBois, Shivaani Kummar et al. · The Lancet Oncology · 2020
Cited by 1,020 works. doi:10.1016/s1470-2045(19)30856-3
Authors
- David S. Hong
- Steven G. DuBois
- Shivaani Kummar
- Anna F. Farago
- Catherine Michelle Albert
- Kristoffer Staal Rohrberg
- Cornelis Martinus van Tilburg
- Ramamoorthy Nagasubramanian
- Jordan D. Berlin
- Noah C. Federman
- Leo Mascarenhas
- Birgit Geoerger
- Afshin Dowlati
- Alberto S. Pappo
- Stefan Bielack
- François Doz
- Ray McDermott
- Jyoti D. Patel
- Russell J. Schilder
- Makoto Tahara
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
- Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma
- Mammary Analogue Secretory Carcinoma of Salivary Glands, Containing the ETV6-NTRK3 Fusion Gene: A Hitherto Undescribed Salivary Gland Tumor Entity
- NTRK fusion-positive cancers and TRK inhibitor therapy
- Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)